US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

GeoVax Labs Inc

0.0267

0.0000

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:0.0267

Open:0.0267

Low:0.0267

Close:0.0267

Loading ...

Overview Company News Filings

GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health

GeoVax to Present at the Emerging Growth Conference on February 19, 2025

GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award

GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs

GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference

GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative

Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability

GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GOVXW/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GOVXW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GOVXW\",,,,,undefined,":{"symbol":"GOVXW","market":"US","secType":"STK","nameCN":"GeoVax Labs Inc","latestPrice":0.0267,"timestamp":1752868800000,"preClose":0.0267,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"07-18 16:00:00 EDT","open":0.0267,"high":0.0267,"low":0.0267,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0267,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GOVXW\",,,,,undefined,":{"symbol":"GOVXW","floatShares":0,"roa":"-915.19%","roe":"-78814.57%","lyrEps":0,"shares":0,"dividePrice":0,"high":0.0267,"amplitude":0,"preClose":0.0267,"low":0.0267,"week52Low":0.0141,"pbRate":"0.00","psRate":"0.00","week52High":0.65,"institutionHeld":0,"latestPrice":0.0267,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.0267,"prevYearClose":0.1001,"prevWeekClose":0.0201,"prevMonthClose":0.0251,"prevQuarterClose":0.0251,"fiveDayClose":0.0201,"twentyDayClose":0.0362,"sixtyDayClose":0.0302},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GOVXW\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512165982","title":"GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165982","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512165982?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:25","pubTimestamp":1739888744,"startTime":"0","endTime":"0","summary":"GeoVax's Vaccine Development Programs Align with Anticipated HHS Focus on Vaccine Safety, Diversification and Domestic Biosecurity. GeoVax's Commitment to a Robust, Transparent and Secure Vaccine Future. GeoVax's mission aligns closely with the new administration's policy priorities, particularly in reducing reliance on foreign pharmaceutical supply chains, increasing vaccine safety and durability, and ensuring access for underserved populations. The Company's proprietary Modified Vaccinia Ankara  platform offers a promising alternative to other vaccine technologies such as mRNA, providing broad-spectrum, durable immunity across multiple infectious diseases via a recognized safe vaccine platform.Diversified Vaccine Development GeoVax's GEO-CM04S1, a next-generation COVID-19 vaccine, and GEO-MVA, a dual-purpose Mpox and smallpox vaccine, align with the advocacy for alternative vaccine platforms beyond mRNA. These vaccines are designed to offer long-term immunity with a well-documented s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-pledges-continued-support-vaccine-142544650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HHS","GOVX","BK4232","BK4548","BNTX","BK4535","BK4588","BK4585","BK4009","R","GOVXW","BK4139","BK4022","BK4551","BK4568"],"gpt_icon":0},{"id":"2512928972","title":"GeoVax to Present at the Emerging Growth Conference on February 19, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512928972","media":"NewMediaWire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512928972?lang=en_us&edition=fundamental","pubTime":"2025-02-17 22:00","pubTimestamp":1739800800,"startTime":"0","endTime":"0","summary":"Company to Provide an Update on Its Mpox Vaccine Program. ATLANTA, GA - February 17, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the next Emerging Growth Conference being held February 18-19, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman and CEO, David Dodd, in real time.Mr. Dodd will present at 2:55 pm ET on Wednesday, February 19, 2025, focusing on the development of GEO-MVA, GeoVax's vaccine candidate for Mpox and smallpox. Following his presentation, Mr. Dodd will open the floor for questions. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event and Mr. Dodd will do his best to get through as many of them as possible.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-present-emerging-growth-conference-140000833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","BK4139","BK4022","BK4548","BK4232","BK4568","BK4588","BNTX","GOVX","R","BK4585","BK4551","BK4583","GOVXW"],"gpt_icon":0},{"id":"2510638246","title":"GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2510638246","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510638246?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:00","pubTimestamp":1739282400,"startTime":"0","endTime":"0","summary":"Recognizing a Visionary Leader in Advancing Healthcare Access for Minority and Vulnerable Populations Worldwide. ATLANTA, GA - February 11, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, proudly congratulates Dr. Valerie Montgomery Rice, President and CEO of Morehouse School of Medicine, on being honored with the 2025 Healthcare Champions Lifetime Achievement Award by the Atlanta Business Chronicle. This prestigious award recognizes Dr. Montgomery Rice's exceptional contributions to healthcare and her unwavering commitment to advancing health equity, particularly among underserved and minority populations globally.In December 2022, Dr. Montgomery Rice joined GeoVax as a Special Advisor to the Chairman, CEO, and Board of Directors. Her expertise has been invaluable in guiding the Company's mission to develop innovative vaccines and immunotherapies that address the needs of underserved populations.GeoVa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-congratulates-dr-valerie-montgomery-140000050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVX","BK4180","BK4535","R","BK4139","BK4137","BK4588","LCUT","BK4548","BK4551","BK4022","BK4568","BK4585","BNTX","HCSG","BK4232","GOVXW"],"gpt_icon":0},{"id":"2509281733","title":"GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2509281733","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509281733?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:00","pubTimestamp":1738764000,"startTime":"0","endTime":"0","summary":"Strategic Progress Across COVID-19, Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum. GEO-CM04S1 continues to demonstrate potential for both immunocompromised patients and as a booster vaccine for those previously inoculated with mRNA vaccines. In 2025, the Company anticipates completion of the evaluation trial among Chronic Lymphocytic Leukemia  patients, a patient population recognized to currently have minimal COVID-19 vaccine options. Interim data reported in Q4 2024 suggest GEO-CM04S1 may offer superior immune responses to CLL patients compared to an mRNA vaccine.GeoVax also expects to report final results from its healthy adults booster trial, offering valuable data on the vaccine's safety and immunogenicity profile. Another pivotal milestone for GEO-CM04S1 in 2025 is the anticipated initiation of patient enrollment in the BARDA-funded Project NextGen Phase 2b trial, which will evaluate GEO-CM04S1 compared to an authorized mRNA vaccine within a 10,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-anticipates-significant-2025-progress-140000731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065732104.USD","BK4022","BNTX","PRGS","BK4097","R","BK4551","BK4139","GOVX","BK4535","BK4568","BK4232","BK4588","BK4548","BK4585","GOVXW"],"gpt_icon":0},{"id":"2508452379","title":"GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the  2025 BIO CEO & Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2508452379","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508452379?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:00","pubTimestamp":1738677600,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - February 4, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present GeoVax's 2025 strategic vision and milestones at the 2025 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 10-12, 2025.GeoVax senior management will also conduct one-on-one meetings throughout the conference. For more information or to schedule a meeting, please visit the conference page here or contact GeoVax Investor Relations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-showcase-advancements-vaccines-immunotherapies-140000253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVX","LU1169589451.USD","BK4588","BK4568","R","LU1169590202.USD","BK4022","BK4121","BK4535","BK4548","BK4551","GOVXW","BK4232","BK4585","BIO","BNTX","BK4139"],"gpt_icon":0},{"id":"2508314656","title":"GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2508314656","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508314656?lang=en_us&edition=fundamental","pubTime":"2025-02-03 22:00","pubTimestamp":1738591200,"startTime":"0","endTime":"0","summary":"Harnessing AI to Revolutionize Vaccine and Therapy Development. ATLANTA, GA - February 3, 2025  - GeoVax Labs, Inc. , a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J. Trump's Stargate Initiative, which aims to harness advanced technologies including Artificial Intelligence  to strengthen U.S. healthcare, biosecurity, and global innovation leadership. This announcement aligns with GeoVax's commitment to leveraging AI across its vaccine and cancer immunotherapy programs to accelerate research, optimize operations, and deliver life-saving solutions.GeoVax has embedded AI into its platforms for vaccine development and cancer immunotherapy, enabling groundbreaking advances:. Vaccine Development: AI drives target discovery and design for vaccines using the Modified Vaccinia Ankara  platform, including GEO-CM04S1, GeoVax's next-generation vaccine for COVID-19, and vaccines for Mpox and Smallpox. AI predicts pathogen mutations, ensuring ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-announces-strategic-integration-ai-140000457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVX","BK4583","BK4022","BK4568","R","GOVXW","BK4139","BK4548","BK4535","BK4588","BK4232","BK4551","BK4585","BNTX"],"gpt_icon":0},{"id":"2507663991","title":"Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability","url":"https://stock-news.laohu8.com/highlight/detail?id=2507663991","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507663991?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:00","pubTimestamp":1738159200,"startTime":"0","endTime":"0","summary":"Addressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness. ATLANTA, GA - January 29, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing vaccines and immunotherapies, today highlighted that it is committed to playing a pivotal role in reinforcing America's biosecurity through its GEO-MVA vaccine, designed to combat both smallpox and Mpox. In light of recent global health challenges, the United States has recognized the critical need to reduce dependence on foreign vaccine suppliers and bolster domestic production capabilities.The 2022 Mpox pandemic significantly depleted the U.S. Strategic National Stockpile  of vaccines, exposing vulnerabilities in the nation's preparedness for emerging health threats. Compounding this issue is the nation's reliance on a single foreign manufacturer for smallpox and Mpox vaccines. This dependency poses a strategic risk, especially considering the current Clade I Mpox outbreak in Africa, characterized","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strengthening-americas-biosecurity-geovax-advances-140000132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4585","BK4568","BK4022","BK4588","BK4535","BNTX","LU1169589451.USD","GOVX","BK4139","GOVXW","BK4232","BK4583","LU1169590202.USD","R","BIO","BK4548","BK4121"],"gpt_icon":0},{"id":"2506370421","title":"GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2506370421","media":"NewMediaWire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506370421?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:00","pubTimestamp":1737986400,"startTime":"0","endTime":"0","summary":"Process Expected to Increase Production Yield, Flexibility at Lower Cost. ATLANTA, GA - January 27, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company specializing in vaccines and immunotherapies, has shared updates about its development-stage advanced Modified Vaccinia Ankara  vaccine manufacturing process. This anticipated process provides the potential to not only address today's pressing health challenges but also paves the way for more efficient, flexible and lower-cost MVA-vaccine manufacturing.The MVA platform is uniquely designed to incorporate multiple antigens into a single vaccine. This versatility allows GeoVax to develop vaccines targeting multiple aspects of a single pathogen or several pathogens simultaneously. Originally developed as a safer smallpox vaccine, the MVA platform offers distinct advantages, including:. Protection against diseases such as Mpox and smallpox.This advanced MVA manufacturing process is expected to significantly simplify vaccine p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-advanced-mva-manufacturing-process-140000479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4232","BK4548","BK4585","R","IE00B7SZL793.SGD","BK4568","BK4539","CEF","BK4022","BNTX","IE00B19Z4B17.USD","LU2286300806.USD","BK4551","AEIS","BK4535","BK4097","BK4139","IE00B66KJ199.SGD","IE0031619046.USD","BK4588","BK4157","BK4560","GOVXW","BK4561","S","GOVX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GOVXW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-08-03","symbol":"GOVXW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1659499200000,"reportTimeType":"post","actualEps":null},{"date":"2022-04-27","symbol":"GOVXW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1651089600000,"name":null,"time":"Post Market","dateTimestamp":1651032000000,"actualEps":null},{"date":"2022-03-09","symbol":"GOVXW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1646859600000,"name":null,"time":"Post Market","dateTimestamp":1646802000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GOVXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GOVXW\",market:\"US\",delay:false,,,undefined,":{}}}